Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) major shareholder Global Strategic Fund I. Venbio bought 127,515 shares of the business’s stock in a transaction on Monday, November 13th. The shares were acquired at an average price of $14.00 per share, for a total transaction of $1,785,210.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Major shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) opened at $14.10 on Tuesday. Apellis Pharmaceuticals, Inc. has a 52-week low of $13.15 and a 52-week high of $14.90.

COPYRIGHT VIOLATION WARNING: This news story was reported by Watch List News and is the sole property of of Watch List News. If you are accessing this news story on another domain, it was illegally stolen and republished in violation of international copyright laws. The legal version of this news story can be read at https://www.watchlistnews.com/apellis-pharmaceuticals-inc-apls-major-shareholder-global-strategic-fund-i-venbio-buys-127515-shares-of-stock/1701656.html.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company focuses on the discovery and development of therapeutic compounds for autoimmune and inflammatory diseases. The Company’s lead compounds are designed to inhibit complement component 3 (C3), the central protein in the complement cascade.

Receive News & Ratings for Apellis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apellis Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.